title: Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
abstract: We compared outcomes of percutaneous coronary intervention patients who received biodegradable-polymer biolimus-eluting stents with those who received durable-polymer everolimus-eluting stents. At Tehran Heart Center, we performed a retrospective analysis of the data from January 2007 through December 2011 on 3,270 consecutive patients with coronary artery disease who underwent percutaneous coronary intervention with the biodegradable-polymer biolimus-eluting stent or the durable-polymer everolimus-eluting stent. We excluded patients with histories of coronary artery bypass grafting or percutaneous coronary intervention, acute ST-segment-elevation myocardial infarction, or the implantation of 2 different stent types. Patients were monitored for 12 months. The primary endpoint was a major adverse cardiac event, defined as a composite of death, nonfatal myocardial infarction, and target-vessel and target-lesion revascularization. Durable-polymer everolimus-eluting stents were implanted in 2,648 (81%) and biodegradable-polymer biolimus-eluting stents in 622 (19%) of the study population. There was no significant difference between the 2 groups (2.7% vs 2.7%; P=0.984) in the incidence of major adverse cardiac events. The cumulative adjusted probability of major adverse cardiac events in the biodegradable-polymer biolimus-eluting stent group did not differ from that of such events in the durable-polymer everolimus-eluting stent group (hazard ratio=0.768; 95% confidence interval, 0.421-1.44; P=0.388). We conclude that in our patients the biodegradable-polymer biolimus-eluting stent was as effective and safe, during the 12-month follow-up period, as was the durable-polymer everolimus-eluting stent.
authors.forename: Ehsan
authors.initials: E
authors.lastname: Parsa
authors.forename: Sepideh
authors.initials: S
authors.lastname: Saroukhani
authors.forename: Fereshteh
authors.initials: F
authors.lastname: Majlessi
authors.forename: Hamidreza
authors.initials: H
authors.lastname: Poorhosseini
authors.forename: Masoumeh
authors.initials: M
authors.lastname: Lofti-Tokaldany
authors.forename: Arash
authors.initials: A
authors.lastname: Jalali
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Salarifar
authors.forename: Ebrahim
authors.initials: E
authors.lastname: Nematipour
authors.forename: Mohammad
authors.initials: M
authors.lastname: Alidoosti
authors.forename: Hassan
authors.initials: H
authors.lastname: Aghajani
authors.forename: Alireza
authors.initials: A
authors.lastname: Amirzadegan
authors.forename: Seyed Ebrahim
authors.initials: SE
authors.lastname: Kassaian
mesh_terms: D020341:Absorbable Implants; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011108:Polymers; D011474:Prosthesis Design; D012042:Registries; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011108:Polymers; D000068338:Everolimus; C518022:umirolimus; D020123:Sirolimus
keywords: Absorbable implants; drug-eluting stents; percutaneous coronary intervention; polymers; stents; treatment outcome